SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

2.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

3.

Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.

4.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

5.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot